Contract Notice Detail

Summary Information

Summary Information
11,700.000000 Euro
 
10C0567924 
Aquisição de PALIPERIDONA IM 175MG e PALIPERIDONA IM 263MG, ao abrigo do CPA 2022/19, para a ULSASI, para o ano 2024 
Tendering Phase
Awarded
Aquisição de PALIPERIDONA IM 175MG e PALIPERIDONA IM 263MG, ao abrigo do CPA 2022/19, para a ULSASI, para o ano 2024 
VortalGOV - Acquisition under a Framework Agreement (via Direct Award) 
Lot NameLot Base PriceExpected Duration
P1153 - PALIPERIDONA [175 MG; SUSP INJ LP; SERINGA]-60 (Days)
P1154 - PALIPERIDONA [263 MG; SUSP INJ LP; SERINGA]-60 (Days)

Object of the Contract

Object of the Contract
Supplies Acquisition 
Ic19 Amadora 2700 Venteira Amadora Lisboa PORTUGAL  
33600000-6 - Pharmaceutical products
 
 
 

Scheduling

Scheduling
6/21/2024 7:34 PM (UTC +1 hour)
 
5/2/2022 7:29 PM (UTC +1 hour)
 
6/25/2024 5:00 PM (UTC +1 hour)
 

Financial Settings

Financial Settings
No 

Contract Documents

Contract Documents
Document NameDescriptionDoc Classification
Anexo II.xlsxAnexo II.xlsxAdditional InformationDownload
Convite_10C0567924.pdfConvite_10C0567924.pdfInstruction to tenderersDownload

Object of contract

No 
No 

Legal, economic, financial and technical information

No 

Questionnaire

Questionnaire
1
Lot Title
P1153 - PALIPERIDONA [175 MG; SUSP INJ LP; SERINGA]
Base Price
5 049,480000

1.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
P1153 PALIPERIDONA [175 MG; SUSP INJ LP; SERINGA] 12,000000 UN
Buyer Comment: 500189412 | Janssen - Cilag Farmacêutica, Lda. | CPA:2022019/74/0055 | NºAIM:5683974;
TOTAL (The amounts shown do not include VAT)
2
Lot Title
P1154 - PALIPERIDONA [263 MG; SUSP INJ LP; SERINGA]
Base Price
6 650,520000

2.1   Bill of Quantities  *  
This price list has extra requirements. Make sure everything is completed, under each article line.

Item Code Description Quantity Unit
P1154 PALIPERIDONA [263 MG; SUSP INJ LP; SERINGA] 12,000000 UN
Buyer Comment: 500189412 | Janssen - Cilag Farmacêutica, Lda. | CPA:2022019/74/0056 | NºAIM:5683958;
TOTAL (The amounts shown do not include VAT)

Evaluation

Evaluation
Vision

Avaliação

Definir modelo de avaliação
Modalidade de avaliação
Método de Avaliação
Divulgar critérios de avaliação

Critérios da Avaliação

1 - P1153 - PALIPERIDONA [175 MG; SUSP INJ LP; SERINGA]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.Preço-100%

Normas de desempate

2 - P1154 - PALIPERIDONA [263 MG; SUSP INJ LP; SERINGA]

Critérios da Avaliação

Descrição
Tipo de Fator
Peso (%)
1.Preço-100%

Normas de desempate

Public Messages

Public Messages
TypeReferenceSubjectDate
No items found...